Vitamin B3
The Most Effective HDL Raiser We Have

Vitamin B3 — The Most Effective HDL Raiser We Have

Niacin — vitamin B3, nicotinic acid — is one of the oldest lipid-modifying agents in medicine. Before statins existed, niacin was the primary tool for managing dyslipidemia. It remains, to this day, the single most potent agent for raising HDL cholesterol — the “good” cholesterol that transports excess cholesterol from arterial walls back to the liver for disposal. No drug or supplement does it better. At therapeutic doses (1–3g/day), niacin increases HDL by 16–25%.

Niacin also reduces LDL, reduces triglycerides, and shifts LDL particle size from the small dense pattern (most atherogenic) to the large buoyant pattern (less harmful). The lipid profile improvement is comprehensive. The Coronary Drug Project, a long-running clinical trial that ended in 1975, found that niacin versus placebo produced a 14% reduction in cardiovascular death, 26% reduction in strokes, and 11% lower overall mortality at 15-year follow-up. These were meaningful numbers.

The Complicated Recent History

The niacin story became complicated in the 2010s. Two large, well-designed randomized trials — AIM-HIGH and HPS2-THRIVE — added niacin to statin therapy and looked for additional cardiovascular benefit. Neither trial found a significant reduction in major cardiovascular events despite the expected lipid improvements. The trials suggested that raising HDL pharmacologically did not translate to the cardiovascular protection that epidemiological HDL data had predicted.

More recently, a 2024 NIH-funded study found that a metabolite of niacin — 2PY, produced when niacin is broken down in the body — was associated with elevated inflammatory markers and increased risk of cardiovascular events. The findings were observational and generated significant debate, but they added complexity to niacin’s risk-benefit picture. The NIH issued a research brief calling for more investigation before any changes to clinical guidance.

This does not mean niacin is harmful at normal dietary doses or at the lower supplemental doses used for general health support. It means high-dose therapeutic niacin (1g+/day), particularly combined with statins in patients with already-controlled LDL, may not provide the added benefit once assumed and may carry some risk. This is a meaningful distinction.

Niacin in the Context of T2D

For people with type 2 diabetes, niacin raises an additional concern: at therapeutic doses, it can impair insulin sensitivity and raise fasting blood glucose. The mechanism involves niacin’s inhibition of fat cell lipolysis, which paradoxically leads to a rebound in fatty acid release that interferes with insulin signaling. This effect is more pronounced at the 1g+ doses used for lipid management than at dietary or moderate supplemental doses.

At doses in the range of 100–500mg — well above the RDA but below the therapeutic lipid-modifying range — niacin functions as a B vitamin with its cofactor roles in energy metabolism (NAD and NADP synthesis), DNA repair, and cellular redox reactions. At these doses, the glucose effect is minimal and the benefit as a cofactor in metabolic processes is real. This is the range where niacin earns its place in a T2D supplement stack.

The Flush

At doses above roughly 50mg, niacin (nicotinic acid) causes a harmless but dramatic skin flushing response — redness, warmth, and itching that typically peaks 15–30 minutes after taking it and fades within an hour. This is a prostaglandin-mediated vascular response, not an allergic reaction. It is uncomfortable but not dangerous. Taking niacin with food and an aspirin (325mg, 30 minutes before) dramatically reduces the flush. Extended-release or “flush-free” forms (inositol hexanicotinate) exist but have much weaker lipid effects than standard nicotinic acid — the flush-free forms essentially do not work for lipid modification.

How to Take It

For general metabolic support: 100–250mg nicotinic acid with food. This provides cofactor benefits without significant lipid effects or glucose interference. Flush is mild to absent at these doses.

For lipid management (with physician involvement): 500–1500mg/day, titrated slowly to tolerance. This range produces meaningful HDL elevation and should be discussed with and monitored by your doctor, particularly if you have diabetes.

Avoid: Flush-free niacin (inositol hexanicotinate) if your goal is any lipid-modifying effect — the evidence does not support it. Avoid combining high-dose niacin with statins without physician oversight.

This page is for informational purposes only and is not medical advice. Consult your physician before making changes to your medications or supplement regimen.